As these data did not include more recent studies, and BRCA testing is now standard in clinical practice in metastatic PC thanks to the approval of specific treatments, we decided to conduct an updated systematic literature review and meta-analysis with the aim of evaluating the proportion of PC patients with BRCA mutations, dividing the data obtained into subgroups according to the type of mutation (germline or somatic mutations; mutation of BRCA1 and/or BRCA2) and according to the disease setting (any stage or metastatic PC or mCRPC). The gene discussed is BRCA2; the disease is pachyonychia congenita.